Navigation Links
Isis Announces Appointment of B. Lynne Parshall as Chief Operating Officer
Date:12/14/2007

CARLSBAD, Calif., Dec. 14 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) today announced that its Board of Directors has promoted B. Lynne Parshall, J.D. to Chief Operating Officer, effective immediately. Ms. Parshall retains her position as Chief Financial Officer, and is a Director of the Company.

"This promotion is well-deserved, and appropriately reflects the scope of Lynne's responsibilities at Isis," commented Stanley Crooke, M.D., Ph.D., Isis' President and CEO. "Lynne has been an integral part of Isis' management team for many years, and has been performing COO functions now for quite some time. This promotion recognizes her outstanding contributions and the nature of her current role with the Company."

Ms. Parshall joined Isis in November 1991, and she has served as Director since 2000, Executive Vice President since 1995, Chief Financial Officer since 1994 and Secretary since 1991. Ms. Parshall is currently responsible for overseeing the operations of finance, legal, patents, manufacturing and business development and is also very involved in the Company's corporate communications activities. Previously, Ms. Parshall was a Partner with the firm of Cooley Godward LLP, now Cooley Godward Kronish LLP, where she represented several health care companies in a general practice specializing in corporate partnering and other technology-based transactions. Ms. Parshall received her J.D. at Stanford Law School, Stanford, California and her B.A. from Harvard University, Cambridge, Massachusetts. Ms. Parshall is on the board of CardioDynamics International Corporation and is a Trustee of The Bishop School in La Jolla. Ms. Parshall is also a member of the Licensing Executives Society and a member of the Ame
'/>"/>

SOURCE Isis Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
3. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
4. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
5. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
6. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
7. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
8. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
9. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
10. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line
11. CNS Response Announces Fiscal Third Quarter 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/22/2014)... On November 17th Chicago start-up Briteseed ... Medical Technologies Summit in San Francisco to take first ... among Silicon Valley investors and technology elites as the ... also positions Briteseed to move on to the ... and compete with other elite innovation finalists for a ...
(Date:11/22/2014)... Nov. 21, 2014  The element of surprise has ... i.e., they strike without warning. Until now, epidemiologists had ... a viral outbreak, resulting in suboptimal responses to both ... Photo - http://photos.prnewswire.com/prnh/20141121/160242 ... been removed because virus gene structural changes have been ...
(Date:11/21/2014)... --  TRU-D SmartUVC LLC and its UK partners, Rapid ... robot, TRU-D SmartUVC, at FIS 2014 in Harrogate, ... at Stand 23. The conference, hosted by Federation ... largest infection-related event of its kind and brings together ... leading events of its type throughout the world. This annual ...
(Date:11/21/2014)... (PRWEB) November 20, 2014 Author Matthew ... Walk to the Other Side” published as a ... Finalist in the “Fiction: Short Story” category of the ... Keen, President and CEO of USA Book News, said ... and independent publishers, including Simon & Schuster, Penguin, John ...
Breaking Biology Technology:Insight Product Development Accelerator Member Wins MedTech Innovator Award Competition 2Insight Product Development Accelerator Member Wins MedTech Innovator Award Competition 3Viruses' Advantage of Surprise is Lost 2TRU-D SmartUVC to Showcase Superbug-Killing Robot at FIS 2014 2TRU-D SmartUVC to Showcase Superbug-Killing Robot at FIS 2014 3Mystic Ink 's Short Story Collection “A Short Walk to the Other Side” Honoring Ray Bradbury Praised As Award-Winning Finalist In USA Best Book Awards 2Mystic Ink 's Short Story Collection “A Short Walk to the Other Side” Honoring Ray Bradbury Praised As Award-Winning Finalist In USA Best Book Awards 3Mystic Ink 's Short Story Collection “A Short Walk to the Other Side” Honoring Ray Bradbury Praised As Award-Winning Finalist In USA Best Book Awards 4
... , MISSISSAUGA, ON, Nov. 23 /PRNewswire-FirstCall/ - YM ... a life sciences product development company that identifies and ... various stages of development, today reported that Cytopia (ASX:CYT) ... CYT387, a potent, orally-administered JAK1/JAK2 inhibitor. The trial is ...
... , BURNABY, BC, Nov. 23 /PRNewswire/ - Inimex Pharmaceuticals, Inc. ... as its President and CEO. , Abrams brings more than ... He is a co-inventor of the nuclear medicine imaging agent, ... plc where he was Manager, Biomedical Research Worldwide. In 1996, ...
... , , , , , , ... , , AUDIO: ... , Click here for more information. , ... , , , , ...
Cached Biology Technology:YM BIOSCIENCES REPORTS FIRST PATIENT IN PHASE I/II TRIAL OF JAK1/JAK2 INHIBITOR, CYT387 ENROLLED BY CYTOPIA 2YM BIOSCIENCES REPORTS FIRST PATIENT IN PHASE I/II TRIAL OF JAK1/JAK2 INHIBITOR, CYT387 ENROLLED BY CYTOPIA 3YM BIOSCIENCES REPORTS FIRST PATIENT IN PHASE I/II TRIAL OF JAK1/JAK2 INHIBITOR, CYT387 ENROLLED BY CYTOPIA 4YM BIOSCIENCES REPORTS FIRST PATIENT IN PHASE I/II TRIAL OF JAK1/JAK2 INHIBITOR, CYT387 ENROLLED BY CYTOPIA 5Inimex Announces Appointment of New CEO 2Amaizing: Corn genome decoded 2Amaizing: Corn genome decoded 3Amaizing: Corn genome decoded 4
(Date:11/21/2014)... , Nov. 19, 2014  Earlier this year ... New York College, and one of the most prolific ... signals that are transmitted from Smartphones to third party ... Smartphones and has one of the earliest known patents ... its usage in the military, child care, elder care ...
(Date:11/18/2014)... , Nov. 18, 2014  The Secure ... Industry Association today jointly announce the formation of ... release of its Identity and Biometric Entry ... The Framework received official support from BORDERPOL, the ... to improve and provide expertise regarding border security, ...
(Date:11/15/2014)... , Nov. 13, 2014  While we may still be ... McCoy used in "Star Trek" to gain instant access to ... to work with smartphones and tablets for monitoring and measuring ... healthcare world. This may seem a tad Orwellian to some, ... adopt some of these technological opportunities into their healthcare regime. ...
Breaking Biology News(10 mins):Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 2Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 3Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 4Identity Management, Document Authentication and Biometric Companies Form "The Airport Entry and Exit Working Group", Releasing the Framework to Help Guide the Department of Homeland Security and Congress Towards Solutions 2Identity Management, Document Authentication and Biometric Companies Form "The Airport Entry and Exit Working Group", Releasing the Framework to Help Guide the Department of Homeland Security and Congress Towards Solutions 3Americans May Be Ready for a Brave New World of Healthcare 2Americans May Be Ready for a Brave New World of Healthcare 3Americans May Be Ready for a Brave New World of Healthcare 4
... Researchers at Woods Hole Oceanographic Institution (WHOI) have developed ... represent the acoustic equivalent of the leap from black-and-white ... mean a major upgrade in their ability to count ... seas of turbulence. Lead authors Tim Stanton and ...
... limped off the pitch, thereby ending his chances of ... injuries and rehabilitation techniques were once again front and ... to one player,s Achilles tendon is a sign of ... of research. Now Paul Comfort and Earle Abramson,s pioneering ...
... reagents have been developed for C. Elegans micro RNA. ... Silence have created the first class of reagents ... used model organism. Wen-hong Li, from the University ... team of researchers including Dr. Genhua Zheng and Dr. ...
Cached Biology News:Now in broadband: Acoustic imaging of the ocean 2Now in broadband: Acoustic imaging of the ocean 3Now in broadband: Acoustic imaging of the ocean 4Now in broadband: Acoustic imaging of the ocean 5Sports rehabilitation and injury prevention 2
Acrylamide, 500 g. Assay: > 99.9%, acrylic acid: < 0.001%. Conductivity (35%): < 2 umhos/cm.Risks: 45, 46, 48, 23, 24, 25 ; Safety Precautions: 53, 44. Category: Nucleotides & Enzymes & Biochemicals...
Assay Diluent Trial Pack, 4 x 100 mL...
... Immunogen: Synthetic peptide derived from the ... Specificity: Specific for the internall ... Reactivity: Mouse (positive controls: mouse brain ... tissues). Applications: Western blotting Immunohistochemistry(froz) ...
Rabbit anti-Junctophilin-4 (C-term)...
Biology Products: